课题基金 / 基金详情

Rift Valley Fever Virus MP-12 Vaccine Completion

Rift Valley Fever Virus MP-12 Vaccine Completion
裂谷热病毒 MP-12 疫苗完成
批准号:
6845770
负责人:
Clarence J. Peters
金额:
$565.31万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-15 至 2009-09-14

项目摘要

项目成果

Clarence J. Peters的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):裂谷热(RVF)是一种撒哈拉以南非洲的地方性病毒性疾病,是埃及最近几次家禽流行性疾病和流行病的原因。它是一种由蚊子传播的包膜RNA病毒,也通过气溶胶途径传播。在2-6天的潜伏期后,它通常会引起急性发热性疾病,大约10%的人会发展成视网膜炎,1%的人失明,大约1%的人会发展成暴发性的病程,死亡率高达50%。裂谷热病毒是一种高优先级的A类生物恐怖分子。它有可能放大在美国发现的许多蚊子物种并通过它们传播。此前在人类身上的疫苗接种努力包括一种IND福尔马林灭活疫苗。它产生了中和抗体,但它需要三针初级系列和重复的增强剂。为了提高免疫原性,USAMRIID创造了一种名为MP12的活疫苗,该疫苗在5-氟尿嘧啶存在下通过连续传代的方式进行诱变和减毒,随后进行了空斑克隆和扩增。用上世纪80年代初S研制的IND免疫约60名志愿者,一次免疫即可形成保护性抗体,一年后仍保持不变。观察到最小的副作用。自那以后,这种疫苗被认为是获得许可的裂谷热疫苗的首选候选疫苗。该项目将继续这一疫苗的开发,通过使用DNA测序将减毒疫苗与亲本进行比较,以准确识别突变点,并为在DNA序列水平上定量确定减毒病毒的遗传稳定性提供依据。几名在目前IND下接种的志愿者将被接种,我们将通过DNA序列分析来检查恢复的病毒是否有任何逆转的迹象。我们将确定优化的宿主细胞系的生长条件,建立用于进一步生产的主细胞库和病毒种子批次,并编写新的IND以支持疫苗的最终II期和III期临床测试。
英文摘要
DESCRIPTION (provided by applicant): Rift Valley Fever (RVF) is a viral disease endemic to sub-Saharan Africa and has been the cause of several recent epizootics and epidemics in Egypt. It is a mosquito-borne enveloped RNA virus, also infectious via the aerosol route. Following a 2-6 day incubation, it typically causes acute febrile illness, and about 10% of those develop retinitis, 1% blindness, and about 1% develop a fulminant course with up to 50% mortality. RVF virus is a class A high priority bioterrorism agent. It has the potential to amplify and be transmitted by many mosquito species found in the United States. Prior vaccination efforts in humans have included an IND formalin inactivated vaccine. It produced neutralizing antibodies but it required a three-shot primary series and repeated boosters. To enhance immunogenicity, USAMRIID created a live vaccine designated MP12, which was mutagenized and attenuated by serial passage in the presence of 5-fluorouracil with subsequent plaque cloning and amplification. Approximately 60 volunteers were immunized under an IND prepared in the early 1980's. Results were promising in that protective antibodies were formed following one injection, and these remained after one year. Minimal side effects were observed. This vaccine has since been considered a prime candidate for a licensed RVF vaccine. This project will continue this vaccine development by comparing the attenuated vaccine with the parent using DNA sequencing to precisely identify the mutation points and provide a basis to quantitatively determine the genetic stability of the attenuated virus at the DNA sequence level. Several volunteers vaccinated under the present IND will be inoculated, and we will examine recovered virus for any signs of reversion again by DNA sequence analysis. We will determine the growth conditions in an optimized host cell line, establish a master cell bank and viral seed lot to be used for further production, and write a new IND to support final phase II and III clinical testing of the vaccine.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
BSL4 Core
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
海外基金